VICTORIA, BC, Sept. 22, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF)
(FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that its subsidiary, IPA
Europe, has made a substantial investment in its B-Cell Select™
platform at its research division in Oss, The Netherlands,
enabled by investments in additional equipment to automate and
significantly innovate their multi-species,
target-interaction-based single B-cell selection technology and
subsequent single cell cloning, thereby significantly accelerating
the identification of comprehensive panels of diverse lead
therapeutic antibodies. The advanced B Cell Select™ platform
seamlessly integrates into IPA's optimization and antibody
developability profiling workflow.
"Our dedicated and motivated team members are driving the
success our B Cell Select ™ platform expansion. This powerful,
multi-species platform is combined with direct, single B cell
cloning and antibody binding profiling to rapidly identify highly
diverse, clinically relevant antibodies to treat various diseases
involving a broad variety of complex target antigens." stated Debby
Kruijsen, General Manager of IPA Europe.
"Next to its suitability for a broad range of antibody sources,
our advanced B Cell Select™ platform is also compatible with
various target tools, including target-expressing cells, enabling
us to select clones at an early stage of antibody discovery based
on a functional read-out as well." says Ilse Roodink, Scientific
Director of IPA-EU.
Interested in learning more? Our second-generation B Cell Select
platform will be one of IPA's showcased technologies presented at
our webinar "High-Throughput Identification of Genetically
Distinct, Target-Specific Antibodies", airing September 23rd at 11:00 EDT. Click here to register online.
About B Cell Select™
ImmunoPrecise Antibodies' B Cell Select platform enables the
interrogation of a greater diversity of an antibody repertoire than
otherwise possible. By interrogating isolated B-cells, IPA can
analyze full organism repertoires with very little
manipulation. This proprietary platform is species
independent allowing for the generation of antibodies from samples
not possible using other methods. B Cell Select can develop
antibodies from any species (including humans) as well as from any
tissue. As the platform explores the entire antibody repertoire, it
can develop antibodies for anything that is possible in an animal's
immune repertoire including any protein class, complex therapeutic
targets, post-translational modifications, and small
molecules.
The B Cell Select platform enables the interrogation of 10
million blood cells to generate native monoclonal antibodies from
immunized animals that specifically target an antigen. The B
cell selection process takes place early in the antibody
development process allowing for the rapid selection of top
candidates, drastically increasing the success rate of antibody
discovery. The platform also harnesses the power of the immune
system to generate natural pairing of the antibodies produced by
selected B cells. These deliverables in our discovery
programs have less liabilities within the antibody sequences
compared to unnatural pairs from in vitro screening that
could potentially affect manufacturability of the antibodies.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with
end-to-end solutions empowering companies to discover and develop
therapies against any disease. The Company's experience and
cutting-edge technologies enable unparalleled support of its
partners in their quest to bring innovative treatments to the
clinic. ImmunoPrecise's full-service capabilities dramatically
reduce the time required for, and the inherent risk associated
with, conventional multi-vendor product development. For further
information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend",
"should" and similar expressions to identify forward-looking
statements. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light of its
experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the previous quarter ended
April 30, 2020 which can be accessed
at www.sedar.com. The "forward-looking statements"
contained herein speak only as of the date of this press release
and, unless required by applicable law, ImmunoPrecise undertakes no
obligation to publicly update or revise such information, whether
as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. SOURCE ImmunoPrecise Antibodies
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ipa-europe-significantly-expands-its-capabilities-releasing-its-second-generation-b-cell-select--301135411.html
SOURCE ImmunoPrecise Antibodies Ltd.